Carregant...
Clinical Management of Adverse Events Associated with Lorlatinib
Lorlatinib is a novel, highly potent, brain‐penetrant, third‐generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second‐generation ALK TKIs. The safety profile of lorlatini...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693708/ https://ncbi.nlm.nih.gov/pubmed/30890623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0380 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|